EP3052466B1 - Process for the preparation of xanthohumol - Google Patents
Process for the preparation of xanthohumol Download PDFInfo
- Publication number
- EP3052466B1 EP3052466B1 EP14792560.6A EP14792560A EP3052466B1 EP 3052466 B1 EP3052466 B1 EP 3052466B1 EP 14792560 A EP14792560 A EP 14792560A EP 3052466 B1 EP3052466 B1 EP 3052466B1
- Authority
- EP
- European Patent Office
- Prior art keywords
- xanthohumol
- salt
- range
- water
- mixture
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- ORXQGKIUCDPEAJ-YRNVUSSQSA-N xanthohumol Chemical compound COC1=CC(O)=C(CC=C(C)C)C(O)=C1C(=O)\C=C\C1=CC=C(O)C=C1 ORXQGKIUCDPEAJ-YRNVUSSQSA-N 0.000 title claims description 92
- YKGCBLWILMDSAV-GOSISDBHSA-N Isoxanthohumol Natural products O(C)c1c2C(=O)C[C@H](c3ccc(O)cc3)Oc2c(C/C=C(\C)/C)c(O)c1 YKGCBLWILMDSAV-GOSISDBHSA-N 0.000 title claims description 91
- FUSADYLVRMROPL-UHFFFAOYSA-N demethylxanthohumol Natural products CC(C)=CCC1=C(O)C=C(O)C(C(=O)C=CC=2C=CC(O)=CC=2)=C1O FUSADYLVRMROPL-UHFFFAOYSA-N 0.000 title claims description 90
- UVBDKJHYMQEAQV-UHFFFAOYSA-N xanthohumol Natural products OC1=C(CC=C(C)C)C(OC)=CC(OC)=C1C(=O)C=CC1=CC=C(O)C=C1 UVBDKJHYMQEAQV-UHFFFAOYSA-N 0.000 title claims description 90
- 235000008209 xanthohumol Nutrition 0.000 title claims description 90
- 238000000034 method Methods 0.000 title claims description 35
- 230000008569 process Effects 0.000 title claims description 30
- 238000002360 preparation method Methods 0.000 title claims description 11
- 239000002244 precipitate Substances 0.000 claims description 23
- 244000025221 Humulus lupulus Species 0.000 claims description 20
- 235000008694 Humulus lupulus Nutrition 0.000 claims description 20
- 239000000243 solution Substances 0.000 claims description 19
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 18
- 238000000605 extraction Methods 0.000 claims description 17
- 239000000706 filtrate Substances 0.000 claims description 17
- 239000000203 mixture Substances 0.000 claims description 17
- ORTQZVOHEJQUHG-UHFFFAOYSA-L copper(II) chloride Chemical compound Cl[Cu]Cl ORTQZVOHEJQUHG-UHFFFAOYSA-L 0.000 claims description 16
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 claims description 14
- 241000218228 Humulus Species 0.000 claims description 12
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 12
- 150000003839 salts Chemical class 0.000 claims description 10
- 239000002904 solvent Substances 0.000 claims description 10
- 229910052723 transition metal Inorganic materials 0.000 claims description 10
- 229910021592 Copper(II) chloride Inorganic materials 0.000 claims description 8
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 8
- -1 transition metal salt Chemical class 0.000 claims description 7
- ARUVKPQLZAKDPS-UHFFFAOYSA-L copper(II) sulfate Chemical compound [Cu+2].[O-][S+2]([O-])([O-])[O-] ARUVKPQLZAKDPS-UHFFFAOYSA-L 0.000 claims description 4
- 229910000366 copper(II) sulfate Inorganic materials 0.000 claims description 4
- JIAARYAFYJHUJI-UHFFFAOYSA-L zinc dichloride Chemical compound [Cl-].[Cl-].[Zn+2] JIAARYAFYJHUJI-UHFFFAOYSA-L 0.000 claims description 4
- NWONKYPBYAMBJT-UHFFFAOYSA-L zinc sulfate Chemical compound [Zn+2].[O-]S([O-])(=O)=O NWONKYPBYAMBJT-UHFFFAOYSA-L 0.000 claims description 4
- 150000001298 alcohols Chemical class 0.000 claims description 3
- 239000012266 salt solution Substances 0.000 claims description 3
- 150000003624 transition metals Chemical class 0.000 claims description 3
- JPVYNHNXODAKFH-UHFFFAOYSA-N Cu2+ Chemical class [Cu+2] JPVYNHNXODAKFH-UHFFFAOYSA-N 0.000 claims description 2
- PTFCDOFLOPIGGS-UHFFFAOYSA-N Zinc dication Chemical class [Zn+2] PTFCDOFLOPIGGS-UHFFFAOYSA-N 0.000 claims description 2
- 150000003841 chloride salts Chemical class 0.000 claims description 2
- 150000002576 ketones Chemical class 0.000 claims description 2
- 150000002823 nitrates Chemical class 0.000 claims description 2
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 claims description 2
- 239000002994 raw material Substances 0.000 claims description 2
- 150000003467 sulfuric acid derivatives Chemical class 0.000 claims description 2
- 239000011592 zinc chloride Substances 0.000 claims description 2
- 235000005074 zinc chloride Nutrition 0.000 claims description 2
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 12
- 230000000694 effects Effects 0.000 description 11
- 239000012528 membrane Substances 0.000 description 7
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 6
- 238000004128 high performance liquid chromatography Methods 0.000 description 6
- 150000002632 lipids Chemical class 0.000 description 6
- 230000000052 comparative effect Effects 0.000 description 4
- 150000001875 compounds Chemical class 0.000 description 4
- 238000004519 manufacturing process Methods 0.000 description 4
- 238000010907 mechanical stirring Methods 0.000 description 4
- 230000007246 mechanism Effects 0.000 description 4
- 238000001556 precipitation Methods 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 3
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 3
- 239000007864 aqueous solution Substances 0.000 description 3
- 238000001914 filtration Methods 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- BDAGIHXWWSANSR-UHFFFAOYSA-N Formic acid Chemical compound OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 2
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 2
- 235000013405 beer Nutrition 0.000 description 2
- 230000004071 biological effect Effects 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 229910002092 carbon dioxide Inorganic materials 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 235000019253 formic acid Nutrition 0.000 description 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 238000005502 peroxidation Methods 0.000 description 2
- 150000008442 polyphenolic compounds Chemical class 0.000 description 2
- 235000013824 polyphenols Nutrition 0.000 description 2
- 230000001376 precipitating effect Effects 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 229920005989 resin Polymers 0.000 description 2
- 239000011347 resin Substances 0.000 description 2
- 125000001424 substituent group Chemical group 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 229910000368 zinc sulfate Inorganic materials 0.000 description 2
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 1
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 1
- 208000024827 Alzheimer disease Diseases 0.000 description 1
- 102000014654 Aromatase Human genes 0.000 description 1
- 108010078554 Aromatase Proteins 0.000 description 1
- 201000006474 Brain Ischemia Diseases 0.000 description 1
- DQFBYFPFKXHELB-UHFFFAOYSA-N Chalcone Natural products C=1C=CC=CC=1C(=O)C=CC1=CC=CC=C1 DQFBYFPFKXHELB-UHFFFAOYSA-N 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- JJLJMEJHUUYSSY-UHFFFAOYSA-L Copper hydroxide Chemical compound [OH-].[OH-].[Cu+2] JJLJMEJHUUYSSY-UHFFFAOYSA-L 0.000 description 1
- 239000005750 Copper hydroxide Substances 0.000 description 1
- 102000003915 DNA Topoisomerases Human genes 0.000 description 1
- 108090000323 DNA Topoisomerases Proteins 0.000 description 1
- 102000002148 Diacylglycerol O-acyltransferase Human genes 0.000 description 1
- 108010001348 Diacylglycerol O-acyltransferase Proteins 0.000 description 1
- 101000979342 Homo sapiens Nuclear factor NF-kappa-B p105 subunit Proteins 0.000 description 1
- 239000004201 L-cysteine Substances 0.000 description 1
- 235000013878 L-cysteine Nutrition 0.000 description 1
- 102000003960 Ligases Human genes 0.000 description 1
- 108090000364 Ligases Proteins 0.000 description 1
- 102000043136 MAP kinase family Human genes 0.000 description 1
- 108091054455 MAP kinase family Proteins 0.000 description 1
- 108010057466 NF-kappa B Proteins 0.000 description 1
- 102000003945 NF-kappa B Human genes 0.000 description 1
- 102100023050 Nuclear factor NF-kappa-B p105 subunit Human genes 0.000 description 1
- 102000004005 Prostaglandin-endoperoxide synthases Human genes 0.000 description 1
- 108090000459 Prostaglandin-endoperoxide synthases Proteins 0.000 description 1
- ZONYXWQDUYMKFB-UHFFFAOYSA-N SJ000286395 Natural products O1C2=CC=CC=C2C(=O)CC1C1=CC=CC=C1 ZONYXWQDUYMKFB-UHFFFAOYSA-N 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 1
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 239000012670 alkaline solution Substances 0.000 description 1
- DZHSAHHDTRWUTF-SIQRNXPUSA-N amyloid-beta polypeptide 42 Chemical compound C([C@@H](C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@H](C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)NCC(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(O)=O)[C@@H](C)CC)C(C)C)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@@H](NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC(O)=O)C(C)C)C(C)C)C1=CC=CC=C1 DZHSAHHDTRWUTF-SIQRNXPUSA-N 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 235000013361 beverage Nutrition 0.000 description 1
- 230000006696 biosynthetic metabolic pathway Effects 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 230000021164 cell adhesion Effects 0.000 description 1
- 230000022131 cell cycle Effects 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 230000012292 cell migration Effects 0.000 description 1
- 150000001789 chalcones Chemical class 0.000 description 1
- 235000005513 chalcones Nutrition 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 229930002875 chlorophyll Natural products 0.000 description 1
- 235000019804 chlorophyll Nutrition 0.000 description 1
- ATNHDLDRLWWWCB-AENOIHSZSA-M chlorophyll a Chemical compound C1([C@@H](C(=O)OC)C(=O)C2=C3C)=C2N2C3=CC(C(CC)=C3C)=[N+]4C3=CC3=C(C=C)C(C)=C5N3[Mg-2]42[N+]2=C1[C@@H](CCC(=O)OC\C=C(/C)CCC[C@H](C)CCC[C@H](C)CCCC(C)C)[C@H](C)C2=C5 ATNHDLDRLWWWCB-AENOIHSZSA-M 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 239000010949 copper Substances 0.000 description 1
- 229910001956 copper hydroxide Inorganic materials 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 235000015872 dietary supplement Nutrition 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 125000004030 farnesyl group Chemical group [H]C([*])([H])C([H])=C(C([H])([H])[H])C([H])([H])C([H])([H])C([H])=C(C([H])([H])[H])C([H])([H])C([H])([H])C([H])=C(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 229930003949 flavanone Natural products 0.000 description 1
- 150000002207 flavanone derivatives Chemical class 0.000 description 1
- 235000011981 flavanones Nutrition 0.000 description 1
- 229930003935 flavonoid Natural products 0.000 description 1
- 150000002215 flavonoids Chemical class 0.000 description 1
- 235000017173 flavonoids Nutrition 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 125000002686 geranylgeranyl group Chemical group [H]C([*])([H])/C([H])=C(C([H])([H])[H])/C([H])([H])C([H])([H])/C([H])=C(C([H])([H])[H])/C([H])([H])C([H])([H])/C([H])=C(C([H])([H])[H])/C([H])([H])C([H])([H])C([H])=C(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000009776 industrial production Methods 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 208000028867 ischemia Diseases 0.000 description 1
- 230000000302 ischemic effect Effects 0.000 description 1
- 238000002386 leaching Methods 0.000 description 1
- 206010025135 lupus erythematosus Diseases 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 210000002569 neuron Anatomy 0.000 description 1
- 230000000324 neuroprotective effect Effects 0.000 description 1
- 230000002887 neurotoxic effect Effects 0.000 description 1
- 238000006386 neutralization reaction Methods 0.000 description 1
- 230000003472 neutralizing effect Effects 0.000 description 1
- 229960002715 nicotine Drugs 0.000 description 1
- SNICXCGAKADSCV-UHFFFAOYSA-N nicotine Natural products CN1CCCC1C1=CC=CN=C1 SNICXCGAKADSCV-UHFFFAOYSA-N 0.000 description 1
- 239000012038 nucleophile Substances 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 230000001590 oxidative effect Effects 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
- 230000004983 pleiotropic effect Effects 0.000 description 1
- 239000002798 polar solvent Substances 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 150000003180 prostaglandins Chemical class 0.000 description 1
- 238000011552 rat model Methods 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 239000010802 sludge Substances 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 125000003396 thiol group Chemical group [H]S* 0.000 description 1
- 238000002604 ultrasonography Methods 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 239000002699 waste material Substances 0.000 description 1
- 150000003751 zinc Chemical class 0.000 description 1
- 229960001763 zinc sulfate Drugs 0.000 description 1
- 239000011686 zinc sulphate Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C45/00—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds
- C07C45/78—Separation; Purification; Stabilisation; Use of additives
- C07C45/85—Separation; Purification; Stabilisation; Use of additives by treatment giving rise to a chemical modification
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/06—Free radical scavengers or antioxidants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C45/00—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds
- C07C45/78—Separation; Purification; Stabilisation; Use of additives
- C07C45/79—Separation; Purification; Stabilisation; Use of additives by solid-liquid treatment; by chemisorption
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C45/00—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds
- C07C45/78—Separation; Purification; Stabilisation; Use of additives
- C07C45/86—Use of additives, e.g. for stabilisation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C49/00—Ketones; Ketenes; Dimeric ketenes; Ketonic chelates
- C07C49/20—Unsaturated compounds containing keto groups bound to acyclic carbon atoms
- C07C49/213—Unsaturated compounds containing keto groups bound to acyclic carbon atoms containing six-membered aromatic rings
- C07C49/215—Unsaturated compounds containing keto groups bound to acyclic carbon atoms containing six-membered aromatic rings polycyclic
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C49/00—Ketones; Ketenes; Dimeric ketenes; Ketonic chelates
- C07C49/76—Ketones containing a keto group bound to a six-membered aromatic ring
- C07C49/782—Ketones containing a keto group bound to a six-membered aromatic ring polycyclic
Definitions
- the invention provides a process for the preparation of high purity xanthohumol from post-extraction spent hops, granulated hop plant or hops. Due to the high purity of the obtained xanthohumol it could be successfully used in dietary supplements, beverages and as a therapeutic product ingredient.
- Xanthohumol (Xn), or (( E )-1-[2,4-dihydroxy-6-methoxy-3-(3-methylbut-2-enyl)-phenyl]-3-(4-hydroxyphenyl)-prop-2-en-1-one) is a naturally-occurring compound of the group of prenylated chalcones, the main source of it being female inflorescence of Humulus Lupus (hop). It is present only in traces in the beer.
- the compound is composed of two benzene rings linked by the ⁇ , ⁇ - unsaturated carbonyl moiety:
- xanthohumol is more lipophilic, the feature being connected with the presence of the prenylated substituent in its structure.
- prenylated (farnesyl or geranylgeranyl) moieties facilitate attachment of numerous intracellurar molecules to a cell membrane, determining their proper activities.
- such moieties can significantly modulate biological activity of the compound, and what is more, influence its physical-chemical properties and sub-cellular distribution.
- xanthohumol reduces inflammatory and oxidative processes by means of various mechanisms.
- the leading ones are: elimination of oxygen free radicals and their reactive forms (RTF), cyclooxygenase (COX I and COX II) activity inhibition, reduction in prostaglandin, NO, TNF ⁇ , NF ⁇ B production and neutralization of membrane phospholipide peroxidation.
- Antioxidative and antiinflammatory activity of xanthohumol is connected with the presence of the hydroxy groups and the prenylated substituent in its molecule. Of importance is also the ⁇ , ⁇ - unsaturated carbonyl moiety. The moiety participates in the Michel reaction with biologically important nucleophiles eg.: L-cysteine in proteins and other sulfhydryl group-containing molecules. In that way, covalent adducts which cause the loss of biological activity of various molecules bound by xanthohumol are obtained.
- xanthohumol activity stems probably from the compound's ability to bind important biological molecules.
- One of the best known examples is the influence of xanthohumol on polymerase ⁇ synthetase, topoisomerase I, alkaline phosphatase, aromatase, diacylglycerol acyltransferase, MAPK signalling pathway proteins, FAK kinase, Akt and STAT or NF- ⁇ B transcription factors.
- Xn-induced reduction of activities of said proteins induces pleiotropic cell effects as a consequence of proliferation, cell cycle, adhesion and migration disturbances in tumorous cells.
- xanthohumol significantly reduces the brain ischemic necrosis area.
- Xanthohumol is thus suggested to reduce also a neurotoxic effect induced by the ⁇ -amyloid peptide (A ⁇ ).
- a ⁇ is known to mediate the free-radical mechanism and is one of the main causes of Alzheimer's disease, by increasing production of free radicals and peroxidation of lipids in nerve cells, which consequently lead to their apoptosis.
- xanthohumol's activity could be connected to its selective activity towards lipid membranes.
- Studies on mechanisms of interaction of xanthohumol with model lipid membranes indicate major modification of dynamic and structural properties of a membrane. Even very small concentrations of xanthohumol strongly interact with hydrophilic fragments of lipid membrane to influence bilayer thickness changes. It is also known that neonicotinoids, due to their high hydrophobicity, penetrate lipid membranes very easily. Interaction of xanthohumol with lipid membrane can significantly reduce its penetration by neonicotinoids, which could explain its strong activity, apart from blocking nicotine receptors.
- xanthohumol is a polyphenol, however, as opposed to polyphenols, it is scarcely soluble in hot water, but dissolves readily in alcohols or water/alcohol mixtures.
- a good source of xanthohumol is the post-extraction spent hops, which comprises wastes from the production of hop extract used by brewing industry for the manufacture of beer.
- the post-extraction spent hops are estimated to contain up to 1% of xanthohumol, depending on the species of a hop plant.
- the application DE 199 39 350 A1 describes a process for the preparation of a xanthohumol-enriched hop extract, wherein mixtures of water and ethanol were used for extraction.
- the obtained extract contained 5 to 15 % of xanthohumol.
- the patent EP 1 424 385 B1 discloses a method of extracting xanthohumol from the raw xanthohumol-containing material by use of compressed CO 2 as a solvent under a pressure above 500 bar and at temperatures above 60°C.
- the application CN 101440029 discloses a method of extracting xanthohumol from the hop plant and xanthohumol-containing products, wherein the extraction with an organic solvent assisted by ultrasounds is conducted, followed by mixing with diatomite, filtering, washing out with water/methanol mixture, concentrating, precipitating and drying to obtain xanthohumol of the 86% purity.
- the patent EP 2 187 899 B1 discloses a process for the preparation of a composition of the high xanthohumol content from a hop plant, wherein a salt is added to a xanthohumol-containing solution to the concentration in the range of from 0.05 to 5.0M, followed by increasing pH to from 10.5 to 12.0, filtering the obtained precipitate, acidifying the filtrate to pH 7-8 to obtain the xanthohumol precipitate of the 40-95% purity.
- the patent US 2009/258094 discloses a process for the preparation of a composition of high xanthohumol content from a hop plant, wherein a salt is added to a xanthohumol-containing solution to the concentration in the range of from 0.05 to 5.0M, followed by adjusting the pH to 9.5-13 to effect formation of a first precipitate, removing the first precipitate to obtain a second solution, adjusting the pH of the second solution to 3-9 to effect formation of a second precipitate, and collecting the second precipitate, wherein the second precipitate contains 40-95% by weight xanthohumol.
- the patent CN 101 811 950 discloses an industrial production method for high purity xanthohumol which comprises leaching a residue of hops which is extracted by carbon dioxide with low level alcohol or acetone solution so that xanthohumol in the residue of hops is fully dissolved, after filtering and collecting the solution and dissolving the clarified solution with strong polar solvents, xanthohumol is extracted and recrystallized.
- the patent application US 11/790,365 discloses a process for the preparation of the powder of the high (60-90%) xanthohumol content, comprising suspending a xanthohumol-enriched extract in an alkaline solution, separating insoluble products, neutralizing and precipitating the dissolved xanthohumol with an acid and isolating the product.
- Patent CN 101433592 discloses use of various adsorption resins to prepare high purity xanthohumol.
- the problem is solved by a newly developed process for the preparation of xanthohumol from post-extraction spent hops, granulated hop plant or hops.
- the invention relates to a process for the preparation of xanthohumol, wherein:
- the concentration of the salt in the mixture is adjusted within the range of from 0.001M to 10M, more preferably in step b) the concentration of the salt in the mixture is adjusted within the range of from 0.001M do 0.05M or above 5M.
- step b additionally after the salt is added in step b:
- step b1) the solution is alkalized to the pH level in the range of 7.5 do 10.5 or above 12.
- the xanthohumol-containing extract is obtained by extraction of the post-extraction spent hops, hops, granulated hop plant or a mixture thereof with an organic water-miscible solvent, the solvent being used in an amount of from 0.1 to 10 liters per 1 kg of the raw material.
- ketones and alcohols or a mixture thereof is used, more preferably, as an organic water-miscible solvent acetone, methanol, ethanol, propanol or a mixture thereof is used.
- the extraction is conducted at a temperature in the range of from 5 to 65°C.
- the xanthohumol-containing extract is mixed with water at a ratio in the range of from 0.1 to 5 liters of water per 1 liter of the extract, more preferably the xanthohumol-containing extract is mixed with water at a ratio in the range of from 1 to 3 liters of water per 1 liter of the extract.
- a concentration of a transition metal salt is provided within the range of from 0.01M to 0.05M.
- a transition metal salt a copper(II) salt or a zinc(II) salt is used.
- a transition metal salt a chloride salt, a nitrate salt, or a sulfate salt is used.
- copper(II) chloride copper(II) sulfate or zinc(II) chloride or zinc(II) sulfate is used.
- the process according to the invention allows to obtain xanthohumol of the purity of at least 90% (usually above 95%) in a good yield.
- the process according to the invention do not require use of complex chromatography systems or supported resins.
- xanthohumol Purity of the obtained xanthohumol was determined by the HPLC technique on the SUPELCOSIL LC-PAH column of 15 cm x 4,6 mm, 5 ⁇ m grain size, column temperature of 20°C, Phase A - 95% acetonitrile 0,3% HCOOH; Phase B - 2% acetonitrile 0,3% HCOOH, 2 ml/min flow rate, 20 ⁇ l injection, detection at the wavelength of 370 and 290 nm.
- the obtained filtrate was acidified with HCl to pH 6 and concentrated on a rotary evaporator to yield a crystalline xanthohumol precipitate which was filtered off and dried in an oven (temperature of 50-60°C) to give 206 mg of xanthohumol of 97.8% HPLC purity.
- the yield of the xanthohumol extraction process was 82% based on the total content of xanthohumol in the spent hops.
- Xanthohumol was obtained as in Example 1, except that after adding copper chloride, the precipitated green sludge was filtered off and the filtrate was concentrated on a rotary evaporator to yield the crystalline xanthohumol precipitate of the 90.8% HPLC purity.
- Xanthohumol was obtained as in Example 1, except that copper chloride was substituted by a zinc sulfate (ZnSO 4 ) solution at the concentration of 10 g/l. After addition of the zinc salt solution, the pH of the solution was stabilized at ⁇ 6, and precipitation was observed. After about an hour NaOH was added with the pH increase to about 10. After 1 h further precipitate was observed at the bottom of the vessel. The precipitate was filtered off on a filter paper.
- ZnSO 4 zinc sulfate
- the obtained filtrate was acidified with HCl do pH 6 and concentrated on a rotary evaporator to yield the crystalline xanthohumol precipitate, which was filtered off and dried in an oven (the temperature of 50-60°C) to give xanthohumol of the 97.8% HPLC purity with the 79% yield based on the total content of xanthohumol in the spent hops.
- Xanthohumol was obtained as in Example 4, except that instead copper(II) chloride, copper(II) sulfate (CuSO 4 ) was used at the concentration of 10 g/l and xanthohumol was obtained with the 94.8% purity.
- Xanthohumol was obtained as in Example 1, except that higher concentrations of copper(II) chloride were used - in the range of 0.022M to 0.044M. Xanthohumol was obtained with the purity ranging from 96.3 - 97.6%.
- Xanthohumol was obtained as in Example 1, except that the ratio of the extract from the first step to the amount of ware added of 1:1 and the CuCl 2 concentration of 0.022M were used, to yield xanthohumol of the 96.3% purity.
- Xanthohumol was obtained as in Example 1, except that 2-propanol in place of acetone and the CuCl 2 concentration of 0,022M were used to yield xanthohumol with the 93.2% purity.
- the obtained filtrate was acidified with HCl to pH 5 and concentrated on a rotary evaporator to obtain a xanthohumol precipitate, which was filtered off and dried in an oven (the temperature of 50-60°C) to yield xanthohumol of the 84.8% HPLC purity.
- Xanthohumol was obtained as in Comparative Example 2, except that NaCl was not used. Xanthohumol was obtained of the 58% HPLC purity - as a result of alkalization to pH 12 only.
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Neurology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Engineering & Computer Science (AREA)
- Rheumatology (AREA)
- Hospice & Palliative Care (AREA)
- Toxicology (AREA)
- Biochemistry (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Extraction Or Liquid Replacement (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Medicines Containing Plant Substances (AREA)
- Jellies, Jams, And Syrups (AREA)
- Compounds Of Unknown Constitution (AREA)
Description
- The invention provides a process for the preparation of high purity xanthohumol from post-extraction spent hops, granulated hop plant or hops. Due to the high purity of the obtained xanthohumol it could be successfully used in dietary supplements, beverages and as a therapeutic product ingredient.
- Xanthohumol (Xn), or ((E)-1-[2,4-dihydroxy-6-methoxy-3-(3-methylbut-2-enyl)-phenyl]-3-(4-hydroxyphenyl)-prop-2-en-1-one) is a naturally-occurring compound of the group of prenylated chalcones, the main source of it being female inflorescence of Humulus Lupus (hop). It is present only in traces in the beer. The compound is composed of two benzene rings linked by the α,β - unsaturated carbonyl moiety:
- The presence of a free hydroxy group in the molecule makes it easily isomerizable to the proper flavanone - an intermediate at the flavonoid biosynthesis pathway. As opposed to other ingredients of hops, xanthohumol is more lipophilic, the feature being connected with the presence of the prenylated substituent in its structure. It should be noted that in living biological systems, the prenylated (farnesyl or geranylgeranyl) moieties facilitate attachment of numerous intracellurar molecules to a cell membrane, determining their proper activities. Likewise, it is suggested that in the case of xanthohumol, such moieties can significantly modulate biological activity of the compound, and what is more, influence its physical-chemical properties and sub-cellular distribution.
- In vitro and in vivo studies suggest also that xanthohumol reduces inflammatory and oxidative processes by means of various mechanisms. The leading ones are: elimination of oxygen free radicals and their reactive forms (RTF), cyclooxygenase (COX I and COX II) activity inhibition, reduction in prostaglandin, NO, TNFα, NFκB production and neutralization of membrane phospholipide peroxidation.
- Antioxidative and antiinflammatory activity of xanthohumol is connected with the presence of the hydroxy groups and the prenylated substituent in its molecule. Of importance is also the α, β - unsaturated carbonyl moiety. The moiety participates in the Michel reaction with biologically important nucleophiles eg.: L-cysteine in proteins and other sulfhydryl group-containing molecules. In that way, covalent adducts which cause the loss of biological activity of various molecules bound by xanthohumol are obtained.
- The broad spectrum of xanthohumol activity stems probably from the compound's ability to bind important biological molecules. One of the best known examples is the influence of xanthohumol on polymerase α synthetase, topoisomerase I, alkaline phosphatase, aromatase, diacylglycerol acyltransferase, MAPK signalling pathway proteins, FAK kinase, Akt and STAT or NF-κB transcription factors. Xn-induced reduction of activities of said proteins induces pleiotropic cell effects as a consequence of proliferation, cell cycle, adhesion and migration disturbances in tumorous cells.
- Noteworthy is also information concerning its neuroprotective properties. In the rat model of MCAO-induced focal ischemia, which reflects focal brain ischemia in vivo, xanthohumol significantly reduces the brain ischemic necrosis area. Xanthohumol is thus suggested to reduce also a neurotoxic effect induced by the β-amyloid peptide (Aβ). Aβ is known to mediate the free-radical mechanism and is one of the main causes of Alzheimer's disease, by increasing production of free radicals and peroxidation of lipids in nerve cells, which consequently lead to their apoptosis.
- Further, apart from its effect on receptors, the mechanism of xanthohumol's activity could be connected to its selective activity towards lipid membranes. Studies on mechanisms of interaction of xanthohumol with model lipid membranes indicate major modification of dynamic and structural properties of a membrane. Even very small concentrations of xanthohumol strongly interact with hydrophilic fragments of lipid membrane to influence bilayer thickness changes. It is also known that neonicotinoids, due to their high hydrophobicity, penetrate lipid membranes very easily. Interaction of xanthohumol with lipid membrane can significantly reduce its penetration by neonicotinoids, which could explain its strong activity, apart from blocking nicotine receptors.
- Concerning its chemical structure, xanthohumol is a polyphenol, however, as opposed to polyphenols, it is scarcely soluble in hot water, but dissolves readily in alcohols or water/alcohol mixtures.
- A good source of xanthohumol is the post-extraction spent hops, which comprises wastes from the production of hop extract used by brewing industry for the manufacture of beer. The post-extraction spent hops are estimated to contain up to 1% of xanthohumol, depending on the species of a hop plant.
- Numerous technologies for the preparation of xanthohumol are known in the art. The application
DE 199 39 350 A1 describes a process for the preparation of a xanthohumol-enriched hop extract, wherein mixtures of water and ethanol were used for extraction. The obtained extract contained 5 to 15 % of xanthohumol. - The patent
EP 1 424 385 B1 discloses a method of extracting xanthohumol from the raw xanthohumol-containing material by use of compressed CO2 as a solvent under a pressure above 500 bar and at temperatures above 60°C. - The application
CN 101440029 discloses a method of extracting xanthohumol from the hop plant and xanthohumol-containing products, wherein the extraction with an organic solvent assisted by ultrasounds is conducted, followed by mixing with diatomite, filtering, washing out with water/methanol mixture, concentrating, precipitating and drying to obtain xanthohumol of the 86% purity. - The patent
EP 2 187 899 B1 discloses a process for the preparation of a composition of the high xanthohumol content from a hop plant, wherein a salt is added to a xanthohumol-containing solution to the concentration in the range of from 0.05 to 5.0M, followed by increasing pH to from 10.5 to 12.0, filtering the obtained precipitate, acidifying the filtrate to pH 7-8 to obtain the xanthohumol precipitate of the 40-95% purity. The patentUS 2009/258094 discloses a process for the preparation of a composition of high xanthohumol content from a hop plant, wherein a salt is added to a xanthohumol-containing solution to the concentration in the range of from 0.05 to 5.0M, followed by adjusting the pH to 9.5-13 to effect formation of a first precipitate, removing the first precipitate to obtain a second solution, adjusting the pH of the second solution to 3-9 to effect formation of a second precipitate, and collecting the second precipitate, wherein the second precipitate contains 40-95% by weight xanthohumol. - The patent
CN 101 811 950 discloses an industrial production method for high purity xanthohumol which comprises leaching a residue of hops which is extracted by carbon dioxide with low level alcohol or acetone solution so that xanthohumol in the residue of hops is fully dissolved, after filtering and collecting the solution and dissolving the clarified solution with strong polar solvents, xanthohumol is extracted and recrystallized. - The patent application
US 11/790,365 - Patent
CN 101433592 discloses use of various adsorption resins to prepare high purity xanthohumol. - In conclusion, analysis of the prior art discloses unequivocally that there is a need for developing a simple and inexpensive process for the preparation of high purity xanthohumol.
- The problem is solved by a newly developed process for the preparation of xanthohumol from post-extraction spent hops, granulated hop plant or hops.
- Thus, the invention relates to a process for the preparation of xanthohumol, wherein:
- a) a xanthohumol-containing extract is mixed with water;
- b) a transition metal salt solution is added to the obtained mixture;
- c) the obtained xanthohumol precipitate is collected and dried to obtain xanthohumol of the purity higher than 90%.
- Preferably, in step b) the concentration of the salt in the mixture is adjusted within the range of from 0.001M to 10M, more preferably in step b) the concentration of the salt in the mixture is adjusted within the range of from 0.001M do 0.05M or above 5M.
- Preferably, additionally after the salt is added in step b:
- b1) the solution is alkalized to the pH level above 7;
- b2) the first precipitate is filtered off, and the filtrate is acidified to the pH level below 7;
- b3) the acidified filtrate is concentrated to obtain the xanthohumol precipitate.
- Preferably, in step b1) the solution is alkalized to the pH level in the range of 7.5 do 10.5 or above 12.
- Preferably, the xanthohumol-containing extract is obtained by extraction of the post-extraction spent hops, hops, granulated hop plant or a mixture thereof with an organic water-miscible solvent, the solvent being used in an amount of from 0.1 to 10 liters per 1 kg of the raw material.
- Preferably, as an organic water-miscible solvent, ketones and alcohols or a mixture thereof is used, more preferably, as an organic water-miscible solvent acetone, methanol, ethanol, propanol or a mixture thereof is used.
- Preferably, the extraction is conducted at a temperature in the range of from 5 to 65°C.
- Preferably, the xanthohumol-containing extract is mixed with water at a ratio in the range of from 0.1 to 5 liters of water per 1 liter of the extract, more preferably the xanthohumol-containing extract is mixed with water at a ratio in the range of from 1 to 3 liters of water per 1 liter of the extract.
- Preferably, in step b) a concentration of a transition metal salt is provided within the range of from 0.01M to 0.05M.
- Preferably, as a transition metal salt a copper(II) salt or a zinc(II) salt is used.
- Preferably, as a transition metal salt a chloride salt, a nitrate salt, or a sulfate salt is used.
- Preferably, as a transition metal salt copper(II) chloride, copper(II) sulfate or zinc(II) chloride or zinc(II) sulfate is used.
- The process according to the invention allows to obtain xanthohumol of the purity of at least 90% (usually above 95%) in a good yield. The process according to the invention do not require use of complex chromatography systems or supported resins.
- Purity of the obtained xanthohumol was determined by the HPLC technique on the SUPELCOSIL LC-PAH column of 15 cm x 4,6 mm, 5 µm grain size, column temperature of 20°C, Phase A - 95% acetonitrile 0,3% HCOOH; Phase B - 2% acetonitrile 0,3% HCOOH, 2 ml/min flow rate, 20 µl injection, detection at the wavelength of 370 and 290 nm.
- The invention was illustrated by the following working examples.
- 250 g of post-extraction spent hops were weighed out and poured over with acetone (0.75 L). After mechanical stirring for 1 h the extract formed was filtered through a filter paper. The obtained filtrate (0.65 L) was flushed with water (1.3 L). Then the solution was added with an aqueous solution of CuCl2 (the concentration of 10 g/l) at the volume of 300 ml per 1 liter of the filtrate (the final concentration of 0,022M). After adding copper chloride, the pH of the solution was stabilized at ∼4,5. Practically immediately after copper chloride pouring, precipitation in the extract occurred of agglomerates of a green substance of residual humulons and chlorophyll separating from a yellow solution where xanthohumol was found. After an hour, NaOH was added to precipitate an excess of copper by raising the pH to about 10. After 1 h, precipitation was observed of a muddy mass and copper hydroxide precipitate at the bottom of the vessel. The precipitates were filtered off on a filter paper. The obtained filtrate was acidified with HCl to pH 6 and concentrated on a rotary evaporator to yield a crystalline xanthohumol precipitate which was filtered off and dried in an oven (temperature of 50-60°C) to give 206 mg of xanthohumol of 97.8% HPLC purity. The yield of the xanthohumol extraction process was 82% based on the total content of xanthohumol in the spent hops.
- Xanthohumol was obtained as in Example 1, except that after adding copper chloride, the precipitated green sludge was filtered off and the filtrate was concentrated on a rotary evaporator to yield the crystalline xanthohumol precipitate of the 90.8% HPLC purity.
- Xanthohumol was obtained as in Example 1, except that copper chloride was substituted by a zinc sulfate (ZnSO4) solution at the concentration of 10 g/l. After addition of the zinc salt solution, the pH of the solution was stabilized at ∼6, and precipitation was observed. After about an hour NaOH was added with the pH increase to about 10. After 1 h further precipitate was observed at the bottom of the vessel. The precipitate was filtered off on a filter paper. The obtained filtrate was acidified with HCl do pH 6 and concentrated on a rotary evaporator to yield the crystalline xanthohumol precipitate, which was filtered off and dried in an oven (the temperature of 50-60°C) to give xanthohumol of the 97.8% HPLC purity with the 79% yield based on the total content of xanthohumol in the spent hops.
- 250 g of post-extraction spent hops were weighed out and poured over with 0,75 liters of pure methanol. After mechanical stirring for 1 h the formed extract was filtered on a filter paper. The obtained filtrate was poured over with water in a volume ratio of 1:2 (one part of the filtrate to two parts of water). Then the solution was added with the aqueous solution of CuCl2 (at the concentration of 10 g/l) in a volume of 300 ml per 1 liter of the filtrate (the final concentration of the salt of 0,022M). After 1 h, precipitation in the extract was observed of agglomerates of a green substance separating from a yellow solution. NaOH was then added to raise the pH to 10. After 1 h, a muddy green precipitate was observed at the bottom of the vessel. The formed extract was filtered on a filter paper. The obtained extract was acidified with HCl to pH 6. The remaining amounts of the solvent were removed on an evaporator and a suspension of xanthohumol crystals was obtained. The suspension was filtered through a filter paper to yield xanthohumol, which was dried in an oven at 55 °C to give 196 mg of xanthohumol of the 95.8% purity with the yield of about 78% based on the total content of xanthohumol in the spent hops.
- Xanthohumol was obtained as in Example 4, except that instead copper(II) chloride, copper(II) sulfate (CuSO4) was used at the concentration of 10 g/l and xanthohumol was obtained with the 94.8% purity.
- Xanthohumol was obtained as in Example 1, except that higher concentrations of copper(II) chloride were used - in the range of 0.022M to 0.044M. Xanthohumol was obtained with the purity ranging from 96.3 - 97.6%.
- Xanthohumol was obtained as in Example 1, except that the ratio of the extract from the first step to the amount of ware added of 1:1 and the CuCl2 concentration of 0.022M were used, to yield xanthohumol of the 96.3% purity.
- Xanthohumol was obtained as in Example 1, except that 2-propanol in place of acetone and the CuCl2 concentration of 0,022M were used to yield xanthohumol with the 93.2% purity.
- 250 g of post-extraction spent hops were weighed out and poured over with acetone (0.75 L). After mechanical stirring for 1 h the extract formed was filtered through a filter paper. The obtained filtrate was concentrated to yield xanthohumol of the 32.8% purity.
- 250 g of post-extraction spent hops were weighed out and poured over with acetone (0.75 L). After mechanical stirring for 1 h the extract formed was filtered through a filter paper. The obtained filtrate (0.65 1) was poured over with water (1.3 1). Then the solution was added with the aqueous solution of NaCl (at the concentration of 30 g/l) at the volume of 300 ml per 1 liter of the filtrate. Then, NaOH was added to raise the pH to about 12. The precipitate formed was filtered off through a filter paper. The obtained filtrate was acidified with HCl to pH 5 and concentrated on a rotary evaporator to obtain a xanthohumol precipitate, which was filtered off and dried in an oven (the temperature of 50-60°C) to yield xanthohumol of the 84.8% HPLC purity.
- Xanthohumol was obtained as in Comparative Example 2, except that NaCl was not used. Xanthohumol was obtained of the 58% HPLC purity - as a result of alkalization to pH 12 only.
- Based on the above-described working examples, it could be ascertained that the process according to the invention allows to obtain xanthohumol of a high purity by an exceptionally simple and inexpensive process. It is obvious for a person skilled in the art that xanthohumol obtained by the inventive process could be further purified according to known methods.
Claims (15)
- A process for the preparation of xanthohumol, characterized in that:a) a xanthohumol-containing extract is mixed with water;b) a transition metal salt solution is added to the obtained mixture;c) the obtained xanthohumol precipitate is collected and dried.
- The process of claim 1, characterized in that in step b) the concentration of the salt in the mixture is adjusted within the range of from 0,001M to 10M.
- The process of claim 2, characterized in that in step b) the concentration of the salt in the mixture is adjusted within the range of from 0,001M to 0,05M.
- The process of any of claims 1-3, characterized in that further after adding the salt in step b:b1) the solution is alkalized to the pH level above 7;b2) the first precipitate is filtered off, and the filtrate is acidified to the pH level below 7;b3) the acidified filtrate is concentrated to obtain the xanthohumol precipitate.
- The process of claim 4, characterized in that in step b1) the solution is alkalized to the pH level in the range of from 7,5 to 10,5.
- The process of any of claims 1-5, characterized in that the xanthohumol-containing extract is obtained by extraction of post-extraction spent hops, hops, granulated hop plant or a mixture thereof with an organic water-miscible solvent, said solvent being used in an amount of from 0,1 to 10 liters per 1 kg of the raw material.
- The process of claim 6, characterized in that as an organic water-miscible solvent, ketones and alcohols or a mixture thereof are used.
- The process of claim 7, characterized in that as an organic water-miscible solvent, acetone, methanol, ethanol, propanol or a mixture thereof is used.
- The process of any of claims 1-8, characterized in that the extraction is conducted at a temperature in the range of from 5 to 65°C.
- The process of any of claims 1-9, characterized in that the xanthohumol-containing extract is mixed with water at a ratio in the range of from 0,1 to 5 liters of water per 1 liter of the extract.
- The process of claim 10, characterized in that the xanthohumol-containing extract is mixed with water at a ratio in the range of from 1 to 3 liters of water per 1 liter of the extract.
- The process of any of claims 1-11, characterized in that in step b) the concentration of a transition metal salt is provided within the range of from 0,01M to 0,05M.
- The process of any of claims 1-12, characterized in that as a transition metal salt, a copper(II) salt or a zinc(II) salt is used.
- The process of any of claims 1-12, characterized in that as a transition metal salt, a chloride salt, a nitrate salt, or a sulfate salt is used.
- The process of any of claims 1-14, characterized in that as a transition metal salt, copper(II) chloride, copper(II) sulfate or zinc(II) chloride or sulfate zinc (II) is used.
Priority Applications (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
RS20180034A RS56756B1 (en) | 2013-10-04 | 2014-09-16 | Process for the preparation of xanthohumol |
MEP-2018-11A ME02981B (en) | 2013-10-04 | 2014-09-16 | Process for the preparation of xanthohumol |
SI201430570T SI3052466T1 (en) | 2013-10-04 | 2014-09-16 | Process for the preparation of xanthohumol |
HRP20180042TT HRP20180042T1 (en) | 2013-10-04 | 2018-01-09 | Process for the preparation of xanthohumol |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PL405540A PL223580B1 (en) | 2013-10-04 | 2013-10-04 | Method for obtaining xanthohumol |
PCT/IB2014/001872 WO2015049561A1 (en) | 2013-10-04 | 2014-09-16 | Process for the preparation of xanthohumol |
Publications (2)
Publication Number | Publication Date |
---|---|
EP3052466A1 EP3052466A1 (en) | 2016-08-10 |
EP3052466B1 true EP3052466B1 (en) | 2017-10-25 |
Family
ID=51844768
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP14792560.6A Active EP3052466B1 (en) | 2013-10-04 | 2014-09-16 | Process for the preparation of xanthohumol |
Country Status (25)
Country | Link |
---|---|
US (1) | US9556097B2 (en) |
EP (1) | EP3052466B1 (en) |
JP (1) | JP6396479B2 (en) |
KR (1) | KR102308524B1 (en) |
CN (1) | CN105829275B (en) |
AU (1) | AU2014330867B2 (en) |
BR (1) | BR112016007460B1 (en) |
CA (1) | CA2926619C (en) |
CL (1) | CL2016000784A1 (en) |
CY (1) | CY1119888T1 (en) |
DK (1) | DK3052466T3 (en) |
ES (1) | ES2657042T3 (en) |
HR (1) | HRP20180042T1 (en) |
HU (1) | HUE037941T2 (en) |
IL (1) | IL244755B (en) |
LT (1) | LT3052466T (en) |
ME (1) | ME02981B (en) |
MX (1) | MX362188B (en) |
PL (1) | PL223580B1 (en) |
PT (1) | PT3052466T (en) |
RS (1) | RS56756B1 (en) |
RU (1) | RU2655926C2 (en) |
SI (1) | SI3052466T1 (en) |
UA (1) | UA116913C2 (en) |
WO (1) | WO2015049561A1 (en) |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
PL242648B1 (en) * | 2017-06-30 | 2023-04-03 | Bioactive Tech Spolka Z Ograniczona Odpowiedzialnoscia | Method for obtaining xanthohumol |
US11026897B2 (en) | 2018-08-10 | 2021-06-08 | Metagenics, Inc. | Composition of curcumagalactomannoside and hops extract |
EP4104818A1 (en) | 2021-06-17 | 2022-12-21 | Skeye Pharma GbR | Ophthalmic composition comprising xanthohumol |
EP4104817A1 (en) | 2021-06-17 | 2022-12-21 | Skeye Pharma GbR | Ophthalmic composition comprising astragaloside iv |
EP4302767A1 (en) | 2022-07-04 | 2024-01-10 | Skeye Pharma GmbH | Ophthalmic composition comprising eriocitrin |
PL441690A1 (en) * | 2022-07-08 | 2024-01-15 | Innox Spółka Z Ograniczoną Odpowiedzialnością | Method of isolation and purification of xanthohumol |
Family Cites Families (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB1274678A (en) | 1968-11-19 | 1972-05-17 | Bush Boake Allen Ltd | Hop extracts |
CN1260122A (en) * | 1999-01-08 | 2000-07-19 | 仲伟德 | Bactericide agricultural chemicals with plant as raw material |
DE19939350B4 (en) | 1999-08-19 | 2005-04-07 | Plantextrakt Gmbh & Co. Kg | Hop extract and process for its preparation |
DE10139479A1 (en) | 2001-08-10 | 2003-02-27 | Schwabe Willmar Gmbh & Co | Hop extracts, process for their preparation and use |
DE10256031A1 (en) | 2002-11-30 | 2004-06-09 | Nateco 2 Gmbh & Co. Kg | Process for the preparation of a xanthohumol-enriched hop extract and its use |
EP1543834A1 (en) | 2003-12-16 | 2005-06-22 | Biodynamics | Production of hop extracts having oestrogenic and antiproliferative bioactivity |
DE102006018988B3 (en) | 2006-04-25 | 2007-08-09 | Nateco2 Gmbh & Co. Kg | Preparing xanthohumol-containing powder with high purity, useful as food additive, comprises preparing xanthohumol-enriched hop extract, separating undissolved by-products, neutralizing and precipitating xanthohumol, separating and drying |
RU2344167C2 (en) * | 2007-03-12 | 2009-01-20 | Общество с ограниченной ответственностью "Дары Кубани" | Hop extract |
EP2187899B1 (en) | 2007-08-15 | 2013-05-15 | Flaxan GmbH & Co. KG | Xanthohumol-enriched hop extract |
US8142821B2 (en) * | 2007-08-15 | 2012-03-27 | Flazan GmbH & Co. KG | Xanthohumol-enriched hop extract |
CN101440029A (en) * | 2008-11-04 | 2009-05-27 | 中国食品发酵工业研究院 | Method for extracting xanthohumol from lupulus |
CN101433592B (en) * | 2008-12-12 | 2011-06-08 | 桂林莱茵生物科技股份有限公司 | Preparation method of Lupulus extract containing xanthohumol |
PL214468B1 (en) | 2009-05-15 | 2013-08-30 | Univ Przyrodniczy We Wroclawiu | Method of obtaining xanthohumol |
CN101811950B (en) * | 2010-05-07 | 2013-01-30 | 玉门拓璞科技开发有限责任公司 | Industrialized production method of high-purity xanthohumol |
-
2013
- 2013-10-04 PL PL405540A patent/PL223580B1/en unknown
-
2014
- 2014-09-16 RU RU2016115081A patent/RU2655926C2/en active
- 2014-09-16 SI SI201430570T patent/SI3052466T1/en unknown
- 2014-09-16 DK DK14792560.6T patent/DK3052466T3/en active
- 2014-09-16 AU AU2014330867A patent/AU2014330867B2/en active Active
- 2014-09-16 RS RS20180034A patent/RS56756B1/en unknown
- 2014-09-16 LT LTEP14792560.6T patent/LT3052466T/en unknown
- 2014-09-16 US US15/027,004 patent/US9556097B2/en active Active
- 2014-09-16 ES ES14792560.6T patent/ES2657042T3/en active Active
- 2014-09-16 EP EP14792560.6A patent/EP3052466B1/en active Active
- 2014-09-16 WO PCT/IB2014/001872 patent/WO2015049561A1/en active Application Filing
- 2014-09-16 PT PT147925606T patent/PT3052466T/en unknown
- 2014-09-16 BR BR112016007460-2A patent/BR112016007460B1/en active IP Right Grant
- 2014-09-16 UA UAA201604939A patent/UA116913C2/en unknown
- 2014-09-16 CN CN201480054359.5A patent/CN105829275B/en active Active
- 2014-09-16 KR KR1020167010538A patent/KR102308524B1/en active IP Right Grant
- 2014-09-16 MX MX2016004128A patent/MX362188B/en active IP Right Grant
- 2014-09-16 HU HUE14792560A patent/HUE037941T2/en unknown
- 2014-09-16 ME MEP-2018-11A patent/ME02981B/en unknown
- 2014-09-16 CA CA2926619A patent/CA2926619C/en active Active
- 2014-09-16 JP JP2016546186A patent/JP6396479B2/en active Active
-
2016
- 2016-03-27 IL IL24475516A patent/IL244755B/en active IP Right Grant
- 2016-04-04 CL CL2016000784A patent/CL2016000784A1/en unknown
-
2018
- 2018-01-09 HR HRP20180042TT patent/HRP20180042T1/en unknown
- 2018-01-22 CY CY20181100075T patent/CY1119888T1/en unknown
Non-Patent Citations (1)
Title |
---|
None * |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP3052466B1 (en) | Process for the preparation of xanthohumol | |
JPH0399090A (en) | Method for preparation of extract containing highly pure anthocyanosides from plant or its extract | |
EP2315596B1 (en) | Process for extraction of glucosinolates from plants | |
Wang et al. | A novel combined process for extracting, separating and recovering flavonoids from flos sophorae immaturus | |
EP1858897A1 (en) | Isolation of galanthamine from biological material | |
SK283953B6 (en) | Method for preparing aloin by extraction | |
CN107848978B (en) | Method for separating bedaquiline diastereoisomer A | |
CN109134331A (en) | The synthetic method of azithromycin genotoxicity impurity | |
RU2411939C1 (en) | Method for synthesis of 2,3,6,7-tetrahydroxynaphthazarin | |
NZ719709B2 (en) | Process for the preparation of xanthohumol | |
CN111601794A (en) | Method for separating gallated epicatechin (EGCG and ECG) from green tea extract or green tea powder | |
KR101153344B1 (en) | Kaempferitrin isolating and purifying method | |
CN111039760A (en) | Method for preparing phenolic compound | |
CN114989163A (en) | Praziquantel synthesis process | |
PL242648B1 (en) | Method for obtaining xanthohumol | |
RU2697197C1 (en) | Method of producing water-soluble salt form of echinochrome a, suitable for use in pharmacological and food industry | |
RU2611409C1 (en) | Method for producing copper complex of chlorophyll | |
US3147246A (en) | Obtention of an alkaloid from nuphar luteum | |
JP4087589B2 (en) | Method for producing camptothecin | |
RU2604030C1 (en) | Method for producing preparation on basis of interaction between trans-dichlorodiammineplatinum (ii) with arabinogalactan | |
PL136525B2 (en) | Method of separation of pure 3-/beta-diethylaminoethyl/-4-methyl-7-hydroxycoumarin hydrochloride | |
PL221810B1 (en) | Method for the extraction of flavanones and chalcones from hops or hop products | |
DK149587B (en) | METHOD OF MORANOLINE PREPARATION | |
SE125110C1 (en) |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
17P | Request for examination filed |
Effective date: 20160330 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR |
|
AX | Request for extension of the european patent |
Extension state: BA ME |
|
GRAP | Despatch of communication of intention to grant a patent |
Free format text: ORIGINAL CODE: EPIDOSNIGR1 |
|
RIC1 | Information provided on ipc code assigned before grant |
Ipc: C07C 45/85 20060101ALI20170206BHEP Ipc: C07C 45/79 20060101ALI20170206BHEP Ipc: C07C 49/84 20060101ALI20170206BHEP Ipc: C07C 45/86 20060101AFI20170206BHEP |
|
GRAJ | Information related to disapproval of communication of intention to grant by the applicant or resumption of examination proceedings by the epo deleted |
Free format text: ORIGINAL CODE: EPIDOSDIGR1 |
|
INTG | Intention to grant announced |
Effective date: 20170314 |
|
GRAP | Despatch of communication of intention to grant a patent |
Free format text: ORIGINAL CODE: EPIDOSNIGR1 |
|
INTG | Intention to grant announced |
Effective date: 20170421 |
|
GRAS | Grant fee paid |
Free format text: ORIGINAL CODE: EPIDOSNIGR3 |
|
GRAJ | Information related to disapproval of communication of intention to grant by the applicant or resumption of examination proceedings by the epo deleted |
Free format text: ORIGINAL CODE: EPIDOSDIGR1 |
|
GRAL | Information related to payment of fee for publishing/printing deleted |
Free format text: ORIGINAL CODE: EPIDOSDIGR3 |
|
GRAR | Information related to intention to grant a patent recorded |
Free format text: ORIGINAL CODE: EPIDOSNIGR71 |
|
GRAA | (expected) grant |
Free format text: ORIGINAL CODE: 0009210 |
|
INTC | Intention to grant announced (deleted) | ||
INTG | Intention to grant announced |
Effective date: 20170914 |
|
AK | Designated contracting states |
Kind code of ref document: B1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR |
|
AX | Request for extension of the european patent |
Extension state: BA ME |
|
REG | Reference to a national code |
Ref country code: GB Ref legal event code: FG4D |
|
REG | Reference to a national code |
Ref country code: CH Ref legal event code: EP |
|
REG | Reference to a national code |
Ref country code: AT Ref legal event code: REF Ref document number: 939757 Country of ref document: AT Kind code of ref document: T Effective date: 20171115 |
|
REG | Reference to a national code |
Ref country code: IE Ref legal event code: FG4D |
|
REG | Reference to a national code |
Ref country code: DE Ref legal event code: R096 Ref document number: 602014016373 Country of ref document: DE |
|
REG | Reference to a national code |
Ref country code: HR Ref legal event code: TUEP Ref document number: P20180042 Country of ref document: HR |
|
REG | Reference to a national code |
Ref country code: DK Ref legal event code: T3 Effective date: 20180118 |
|
REG | Reference to a national code |
Ref country code: RO Ref legal event code: EPE |
|
REG | Reference to a national code |
Ref country code: PT Ref legal event code: SC4A Ref document number: 3052466 Country of ref document: PT Date of ref document: 20180130 Kind code of ref document: T Free format text: AVAILABILITY OF NATIONAL TRANSLATION Effective date: 20180122 |
|
REG | Reference to a national code |
Ref country code: NL Ref legal event code: FP |
|
REG | Reference to a national code |
Ref country code: HR Ref legal event code: T1PR Ref document number: P20180042 Country of ref document: HR |
|
REG | Reference to a national code |
Ref country code: ES Ref legal event code: FG2A Ref document number: 2657042 Country of ref document: ES Kind code of ref document: T3 Effective date: 20180301 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: NO Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20180125 Ref country code: SE Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20171025 Ref country code: FI Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20171025 |
|
REG | Reference to a national code |
Ref country code: SK Ref legal event code: T3 Ref document number: E 26393 Country of ref document: SK |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: LV Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20171025 Ref country code: BG Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20180125 Ref country code: IS Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20180225 |
|
REG | Reference to a national code |
Ref country code: GR Ref legal event code: EP Ref document number: 20180400190 Country of ref document: GR Effective date: 20180518 |
|
REG | Reference to a national code |
Ref country code: DE Ref legal event code: R097 Ref document number: 602014016373 Country of ref document: DE |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: EE Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20171025 |
|
REG | Reference to a national code |
Ref country code: FR Ref legal event code: PLFP Year of fee payment: 5 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: PL Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20171025 Ref country code: SM Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20171025 |
|
PLBE | No opposition filed within time limit |
Free format text: ORIGINAL CODE: 0009261 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT |
|
REG | Reference to a national code |
Ref country code: HU Ref legal event code: AG4A Ref document number: E037941 Country of ref document: HU |
|
26N | No opposition filed |
Effective date: 20180726 |
|
REG | Reference to a national code |
Ref country code: AT Ref legal event code: UEP Ref document number: 939757 Country of ref document: AT Kind code of ref document: T Effective date: 20171025 |
|
REG | Reference to a national code |
Ref country code: HR Ref legal event code: ODRP Ref document number: P20180042 Country of ref document: HR Payment date: 20190925 Year of fee payment: 6 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: MK Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20171025 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: AL Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20171025 |
|
REG | Reference to a national code |
Ref country code: HR Ref legal event code: ODRP Ref document number: P20180042 Country of ref document: HR Payment date: 20200807 Year of fee payment: 7 |
|
REG | Reference to a national code |
Ref country code: HR Ref legal event code: ODRP Ref document number: P20180042 Country of ref document: HR Payment date: 20210729 Year of fee payment: 8 |
|
REG | Reference to a national code |
Ref country code: HR Ref legal event code: ODRP Ref document number: P20180042 Country of ref document: HR Payment date: 20220816 Year of fee payment: 9 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: MC Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20220930 |
|
P01 | Opt-out of the competence of the unified patent court (upc) registered |
Effective date: 20230629 |
|
REG | Reference to a national code |
Ref country code: HR Ref legal event code: ODRP Ref document number: P20180042 Country of ref document: HR Payment date: 20230830 Year of fee payment: 10 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: TR Payment date: 20230831 Year of fee payment: 10 Ref country code: RO Payment date: 20230904 Year of fee payment: 10 Ref country code: NL Payment date: 20230831 Year of fee payment: 10 Ref country code: MC Payment date: 20230925 Year of fee payment: 10 Ref country code: LU Payment date: 20230926 Year of fee payment: 10 Ref country code: IE Payment date: 20230830 Year of fee payment: 10 Ref country code: GB Payment date: 20230830 Year of fee payment: 10 Ref country code: CZ Payment date: 20230904 Year of fee payment: 10 Ref country code: AT Payment date: 20230831 Year of fee payment: 10 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: SK Payment date: 20230905 Year of fee payment: 10 Ref country code: SI Payment date: 20230831 Year of fee payment: 10 Ref country code: RS Payment date: 20230831 Year of fee payment: 10 Ref country code: PT Payment date: 20230831 Year of fee payment: 10 Ref country code: HU Payment date: 20230905 Year of fee payment: 10 Ref country code: HR Payment date: 20230830 Year of fee payment: 10 Ref country code: GR Payment date: 20230831 Year of fee payment: 10 Ref country code: FR Payment date: 20230830 Year of fee payment: 10 Ref country code: DK Payment date: 20230830 Year of fee payment: 10 Ref country code: DE Payment date: 20230831 Year of fee payment: 10 Ref country code: BE Payment date: 20230831 Year of fee payment: 10 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: MT Payment date: 20230905 Year of fee payment: 10 Ref country code: LT Payment date: 20230904 Year of fee payment: 10 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: ES Payment date: 20231017 Year of fee payment: 10 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: IT Payment date: 20230922 Year of fee payment: 10 Ref country code: CY Payment date: 20230831 Year of fee payment: 10 Ref country code: CH Payment date: 20231001 Year of fee payment: 10 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: MC Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20220930 |
|
PGRI | Patent reinstated in contracting state [announced from national office to epo] |
Ref country code: MC Effective date: 20230925 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: MC Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20220930 |
|
PGRI | Patent reinstated in contracting state [announced from national office to epo] |
Ref country code: MC Effective date: 20230925 |